Description
RP2 is currently under investigation for the treatment of colorectal cancer and has shown promise in preclinical studies. Its clinical efficacy and safety profile are still being evaluated in ongoing trials; it is not yet approved by regulatory agencies such as the FDA.
Mechanism of Action
RP2 is an investigational agent that targets a specific pathway involved in colorectal cancer progression, though the exact mechanism of action has not been fully elucidated and requires further research.
Side Effects
Nausea; vomiting; fatigue; diarrhea
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05733611
Phase 2
Terminated
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT04041310
Phase 1
Active, not recruiting
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
United States, Belgium, Canada, Italy, Spain, United Kingdom